ACE and asthma: Achievement improved for two indicators (processes of care for diabetes (OR 1.51; 95% CI 1.15, 1.99) and stroke assessment in atrial fibrillation (5.17; 1.02, 26.2)), and fell for three indicators (asthma review (0.14; 0.11, 0.17), treatment of heart failure with an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) (0.32; 0.12, 0.82), and treatment of heart failure with both an ACE-inhibitor or ARB and a beta-blocker (0.87; 0.27, 2.76)).